Volume 10,Issue 4
Objective: After percutaneous kyphoplasty (PKP), patients with pathological vertebral fractures of thoracolumbar metastases often have Qi and blood deficiency syndrome and hidden blood loss, resulting in postoperative debilitation syndrome. This study aimed to evaluate the clinical efficacy and mechanism of Shenqi Hexue Decoction on early postoperative recovery of such patients. Methods: 36 Patients were randomly divided into an experimental group (Shenqi Hexue Decoction + conventional treatment) and a control group (conventional treatment). The changes of hemoglobin (HB), Karnofsky functional status (KPS) score, and TCM syndrome score on the 1st, 4th, and 7th day after operation were observed. Results: The HB value of the experimental group was significantly higher than that of the control group on the 4th and 7th days after operation (p<0.01), and the maximum decline value of HB decreased by 42.1% (p < 0.001); The improvement rate of KPS score in the experimental group was 94.4% on the 7th day after operation, which was significantly better than 66.7% in the control group (p < 0.05). The total effective rate of TCM syndrome efficacy was 94.4% in the experimental group and 72.2% in the control group (p < 0.05); No drug-related serious adverse reactions were found. Conclusion: Shenqi Hexue decoction can effectively improve the anemia state and activity ability of patients with Qi blood deficiency syndrome in the early stage after PKP, and its possible mechanism involves multi-target regulation such as hematopoietic regulation, microcirculation improvement and inflammation inhibition, with good safety.